Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

allogeneic GM-CSF-secreting myeloma vaccine

An allogeneic plasma cell myeloma vaccine consisting two multiple myeloma cell lines, H929 and U266, admixed with GM-CSF-secreting K562 cells, with potential antineoplastic and immunopotentiating activities. Upon administration, the secreted GM-CSF modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells, with some specificity towards stimulation of leukocyte production, and may reverse treatment-induced neutropenia. This agent also promotes antigen presentation, upregulates antibody-dependent cellular cytotoxicity (ADCC), increases interleukin-2-mediated lymphokine-activated killer cell (LAK) function and may augment host antitumoral immunity. For safety, the myeloma cells are irradiated prior to vaccination.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic GM-CSF-secreting multiple myeloma vaccine
allogeneic GVAX myeloma vaccine
allogeneic myeloma vaccine with GM-CSF-secreting K562 cells
GVAX allogeneic myeloma vaccine
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search